1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Multidrug resistance (MDR) is a serious phenomenon employed by cancer cells which hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR is the overexpression of ATP-binding cassette (ABC) efflux transporters in cancer cells such as P-glycoprotein (P-gp/ABCB1), multidrug resistance-associated protein 2 (MRP2/ABCC2), and breast cancer resistance protein (BCRP/ABCG2) that limits the prolonged and effective use of chemotherapeutic drugs. Researchers have found that developing inhibitors of ABC efflux transporters as chemosensitizers could overcome MDR. But the clinical trials have shown that most of these chemosensitizers are merely toxic and only show limited or no benefits to cancer patients, thus new inhibitors are being explored. Recent findings also suggest that efflux pumps of the ABC transporter family are subject to epigenetic gene regulation. In this review, we summarize recent findings of the role of ABC efflux transporters in MDR.

          Related collections

          Author and article information

          Journal
          Cancer Lett.
          Cancer letters
          1872-7980
          0304-3835
          Jan 1 2016
          : 370
          : 1
          Affiliations
          [1 ] Department of Pharmacy, Anhui Provincial Hospital, 17 Lujiang Road, Hefei, Anhui 230001, China; Institute for Liver Diseases of Anhui Medical University (AMU), Anhui Institute of Innovative Drugs, Anhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, China.
          [2 ] Department of Pharmacy, Anhui Provincial Hospital, 17 Lujiang Road, Hefei, Anhui 230001, China.
          [3 ] Institute for Liver Diseases of Anhui Medical University (AMU), Anhui Institute of Innovative Drugs, Anhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, China.
          [4 ] Department of Pharmacy, Anhui Provincial Hospital, 17 Lujiang Road, Hefei, Anhui 230001, China. Electronic address: ahslyyjl@126.com.
          [5 ] Institute for Liver Diseases of Anhui Medical University (AMU), Anhui Institute of Innovative Drugs, Anhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, China. Electronic address: lj@ahmu.edu.cn.
          Article
          S0304-3835(15)00627-8
          10.1016/j.canlet.2015.10.010
          26499806
          c81adab0-2f60-4d63-b80b-edfc0a9927ec
          Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
          History

          ABC transporters,Cancer therapy,Inhibitors,Multidrug resistance

          Comments

          Comment on this article